BR0315148A - Agregado com deformabilidade aumentada, compreendendo pelo menos três anfipatos, para transporte melhorado através de barreiras semipermeáveis e para aplicação de droga não-invasiva in vivo, especialmente através da pele - Google Patents

Agregado com deformabilidade aumentada, compreendendo pelo menos três anfipatos, para transporte melhorado através de barreiras semipermeáveis e para aplicação de droga não-invasiva in vivo, especialmente através da pele

Info

Publication number
BR0315148A
BR0315148A BR0315148-4A BR0315148A BR0315148A BR 0315148 A BR0315148 A BR 0315148A BR 0315148 A BR0315148 A BR 0315148A BR 0315148 A BR0315148 A BR 0315148A
Authority
BR
Brazil
Prior art keywords
drug
aggregates
application
amphipates
vivo
Prior art date
Application number
BR0315148-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Gregor Cevc
Ulrich Vierl
Original Assignee
Idea Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/357,618 external-priority patent/US20040105881A1/en
Application filed by Idea Ag filed Critical Idea Ag
Publication of BR0315148A publication Critical patent/BR0315148A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR0315148-4A 2002-10-11 2003-10-09 Agregado com deformabilidade aumentada, compreendendo pelo menos três anfipatos, para transporte melhorado através de barreiras semipermeáveis e para aplicação de droga não-invasiva in vivo, especialmente através da pele BR0315148A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41784702P 2002-10-11 2002-10-11
US10/357,618 US20040105881A1 (en) 2002-10-11 2003-02-04 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US10/357,617 US7473432B2 (en) 2002-10-11 2003-02-04 NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
PCT/EP2003/011202 WO2004032900A1 (en) 2002-10-11 2003-10-09 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin

Publications (1)

Publication Number Publication Date
BR0315148A true BR0315148A (pt) 2005-08-16

Family

ID=32995875

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315148-4A BR0315148A (pt) 2002-10-11 2003-10-09 Agregado com deformabilidade aumentada, compreendendo pelo menos três anfipatos, para transporte melhorado através de barreiras semipermeáveis e para aplicação de droga não-invasiva in vivo, especialmente através da pele

Country Status (21)

Country Link
EP (5) EP1815847A3 (OSRAM)
JP (3) JP2006505619A (OSRAM)
KR (1) KR20050055723A (OSRAM)
CN (1) CN1703199B (OSRAM)
AT (1) ATE381316T1 (OSRAM)
AU (1) AU2003273977B2 (OSRAM)
BR (1) BR0315148A (OSRAM)
CA (1) CA2498938A1 (OSRAM)
DE (1) DE60318227T2 (OSRAM)
DK (1) DK1551370T3 (OSRAM)
EA (1) EA010407B1 (OSRAM)
ES (1) ES2298566T3 (OSRAM)
HR (1) HRPK20050421B3 (OSRAM)
IS (1) IS7776A (OSRAM)
MX (1) MXPA05003744A (OSRAM)
NO (1) NO20052281L (OSRAM)
NZ (1) NZ538571A (OSRAM)
PL (1) PL377202A1 (OSRAM)
PT (1) PT1551370E (OSRAM)
SI (1) SI1551370T1 (OSRAM)
WO (1) WO2004032900A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
EP1811961A2 (en) * 2004-11-12 2007-08-01 Idea Ag Extended surface aggregates in the treatment of skin conditions
EP2676680A1 (de) * 2007-09-13 2013-12-25 Basf Se Verwendung von Hydrophobin-Polipeptiden als Penetrationsverstärker
PL214538B1 (pl) * 2009-05-28 2013-08-30 P P F Hasco Lek Spolka Akcyjna Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen
CN105434354A (zh) * 2009-06-03 2016-03-30 斯昆申技术控股有限责任公司 用于治疗深部组织疼痛的制剂
US20120232034A1 (en) 2009-08-21 2012-09-13 Henk-Andre Kroon Vesicular formulations
GB2503845A (en) * 2011-03-21 2014-01-08 Gregor Cevc Optimised preparations of highly adaptable aggregates
GB2503844A (en) * 2011-03-21 2014-01-08 Gregor Cevc Drug-free compositions and methods for diminishing peripheral inflammation and pain
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
CA2889664C (en) * 2012-10-26 2020-12-29 Oxford Nanopore Technologies Limited Droplet interfaces
RU2524649C1 (ru) * 2013-07-24 2014-07-27 Станислав Анатольевич Кедик Способ получения микросфер для приготовления инъецируемой лекарственной формы диклофенака, композиция и лекарственная форма
HK1221412A1 (zh) * 2013-07-31 2017-06-02 Sequessome Technology Holdings Limited 囊泡
EP3760638A3 (en) * 2013-09-26 2021-05-26 National University of Singapore Compositions and methods utilizing lysophosphatidylcholine scaffolds
JP6547625B2 (ja) * 2013-10-25 2019-07-24 凸版印刷株式会社 膜小胞回収デバイス、膜小胞回収方法、及び膜小胞分析方法
ES2879383T3 (es) 2015-06-30 2021-11-22 Sequessome Tech Holdings Limited Fórmulas mixtas
US12364661B2 (en) 2015-11-20 2025-07-22 The Regents Of The University Of California Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
JP7280624B2 (ja) * 2017-04-03 2023-05-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 経血液脳関門的、経粘膜的及び経皮的薬物送達のための変形可能なナノスケールビヒクル(dnv)
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
KR102149190B1 (ko) 2018-04-09 2020-08-28 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
KR102209397B1 (ko) 2020-07-21 2021-01-29 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
DE4107153A1 (de) * 1991-03-06 1992-09-10 Gregor Cevc Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
CA2067754C (en) * 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
CN1320880C (zh) * 1998-12-23 2007-06-13 伊迪亚股份公司 改进的体内局部无创伤用制剂
PT1031347E (pt) * 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis

Also Published As

Publication number Publication date
ES2298566T3 (es) 2008-05-16
KR20050055723A (ko) 2005-06-13
EP1551370B1 (en) 2007-12-19
IS7776A (is) 2005-03-30
DE60318227D1 (de) 2008-01-31
EP1551370A1 (en) 2005-07-13
EA200500632A1 (ru) 2005-12-29
NO20052281D0 (no) 2005-05-10
HRP20050421A2 (en) 2005-12-31
EP1829527A2 (en) 2007-09-05
JP4555111B2 (ja) 2010-09-29
AU2003273977A1 (en) 2004-05-04
NO20052281L (no) 2005-07-07
PT1551370E (pt) 2008-02-07
CA2498938A1 (en) 2004-04-22
SI1551370T1 (sl) 2008-06-30
HRPK20050421B3 (en) 2007-06-30
DK1551370T3 (da) 2008-03-03
EP1829528A2 (en) 2007-09-05
PL377202A1 (pl) 2006-01-23
MXPA05003744A (es) 2005-09-20
EP1829527A3 (en) 2008-11-05
EP1829528A3 (en) 2008-11-05
CN1703199B (zh) 2010-04-28
EP1815846A3 (en) 2008-10-22
EP1815847A2 (en) 2007-08-08
EP1815846A2 (en) 2007-08-08
WO2004032900A1 (en) 2004-04-22
JP2005213261A (ja) 2005-08-11
NZ538571A (en) 2007-05-31
DE60318227T2 (de) 2008-12-04
AU2003273977B2 (en) 2007-07-12
JP2009108070A (ja) 2009-05-21
HK1079113A1 (en) 2006-03-31
JP2006505619A (ja) 2006-02-16
CN1703199A (zh) 2005-11-30
WO2004032900A8 (en) 2005-03-31
EA010407B1 (ru) 2008-08-29
EP1815847A3 (en) 2008-11-05
ATE381316T1 (de) 2008-01-15

Similar Documents

Publication Publication Date Title
WO2004032900A8 (en) Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
ES2602450T3 (es) Composición farmacéutica para uso dérmico para el tratamiento de la psoriasis que comprende calcipotril y betametasona
CY1107299T1 (el) Συμφυρμα με αυξημενh ικανοτητα παραμορφωσης, περιεχοντας τουλαχιστον τρια αμφιπαθη, για βελτιωμενη μεταφορα δια μεσω ημι-διαπερατων μεμβρανων και για τη μη-επεκτατικη εφαρμογη φαρμακων in vivo, ειδικoτερα δια μεσω του δερματος
Almeida et al. Pluronic® F-127 and Pluronic Lecithin Organogel (PLO): Main features and their applications in topical and transdermal administration of drugs
ITMI20021392A1 (it) Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
AR012376A1 (es) Formulacion de gel para la aplicacion topica
JP2005531570A (ja) 貫粘膜薬物送達及び凍結保護のための組成物及び方法
EP1959926A1 (en) Formulation comprising a drug of low water solubility and method of use thereof
EP1100522A4 (en) ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG
KR900015715A (ko) 약물을 함유하는 동결건조 제형물의 제조방법
AR033688A1 (es) Composicion parenteral reconstituible
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
TNSN04023A1 (fr) Formulation de suspension orale stabilisee
EA199900749A1 (ru) Фармацевтическая композиция
BR9901782A (pt) Forma para dosagem de nefazodona.
AR055363A1 (es) Formulaciones farmaceuticas que comprenden un beta 2- agonista de accion prolongada para administracion por nebulizacion
ES2184428T3 (es) Suspension de sustancia activa por via oral.
ATE364391T1 (de) Arzneiformulierung enthaltend ciclosporin und deren verwendung
BR9809571A (pt) Composição medicinal e processo para produzì-la
BR9809708A (pt) Composições farmacêuticas de peptìdeos tendo solubilidade baixa em meio fisiológico
Shi et al. Advances in nanotherapy for targeting senescent cells
BE1000722A4 (fr) Compositions pharmaceutiques de polypeptides adaptees a la resorption gastro-intestinale.
WO2001028538A3 (en) Laxative preparation containing l-arginine
RU96117652A (ru) Двуслойные препараты
ES2881261T3 (es) Protección profiláctica contra infecciones virales

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.